Shares of Envista Holdings Corporation (NYSE:NVST - Get Free Report) have earned a consensus recommendation of "Hold" from the fifteen analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $20.9231.
A number of research firms recently commented on NVST. Mizuho boosted their price target on Envista from $15.00 to $18.00 and gave the company an "underperform" rating in a research note on Friday, August 1st. UBS Group upped their target price on Envista from $18.00 to $22.00 and gave the stock a "neutral" rating in a research report on Tuesday, July 29th. Evercore ISI increased their price target on Envista from $19.00 to $23.00 and gave the company an "outperform" rating in a research report on Wednesday, July 9th. Wall Street Zen upgraded Envista from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 2nd. Finally, Baird R W upgraded Envista from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 27th.
View Our Latest Stock Report on NVST
Envista Stock Down 0.7%
NYSE NVST traded down $0.15 during trading hours on Tuesday, reaching $20.67. 107,567 shares of the company's stock were exchanged, compared to its average volume of 2,596,882. The company's 50-day moving average is $19.81 and its two-hundred day moving average is $18.61. Envista has a one year low of $14.22 and a one year high of $23.00. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.08 and a current ratio of 2.44. The company has a market capitalization of $3.43 billion, a price-to-earnings ratio of 64.58, a price-to-earnings-growth ratio of 1.15 and a beta of 1.00.
Envista (NYSE:NVST - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.02. Envista had a net margin of 2.11% and a return on equity of 4.84%. The company had revenue of $682.10 million during the quarter, compared to analysts' expectations of $638.21 million. During the same period last year, the business earned $0.11 EPS. The business's quarterly revenue was up 7.7% on a year-over-year basis. On average, analysts forecast that Envista will post 1 EPS for the current fiscal year.
Institutional Investors Weigh In On Envista
Several hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC increased its holdings in Envista by 1,338.3% during the 1st quarter. GAMMA Investing LLC now owns 33,139 shares of the company's stock worth $572,000 after purchasing an additional 30,835 shares during the period. Two Sigma Advisers LP increased its holdings in Envista by 66.6% during the 4th quarter. Two Sigma Advisers LP now owns 47,800 shares of the company's stock worth $922,000 after purchasing an additional 19,100 shares during the period. Comerica Bank increased its holdings in Envista by 8.2% during the 4th quarter. Comerica Bank now owns 121,851 shares of the company's stock worth $2,350,000 after purchasing an additional 9,248 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in Envista by 220.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 47,319 shares of the company's stock worth $817,000 after purchasing an additional 32,556 shares during the period. Finally, New York State Common Retirement Fund increased its holdings in Envista by 8.1% during the 1st quarter. New York State Common Retirement Fund now owns 450,101 shares of the company's stock worth $7,769,000 after purchasing an additional 33,855 shares during the period.
About Envista
(
Get Free Report)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Featured Stories

Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.